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Abstract
Aims/hypothesis Glucagon-like peptide-1 (GLP-1) receptor
agonists are currently used for the treatment of type 2 diabetes.
Their main mechanism of action is enhancement of glucose-
induced insulin secretion (from increased beta cell glucose
sensitivity) and inhibition of glucagon secretion. The latter
has been demonstrated to account for about half of their blood
glucose-lowering activity. Whereas the effect of GLP-1 on
insulin secretion is clearly dependent on ambient glucose con-
centrations and has been described in detail, the mechanism
responsible for the inhibitory effect of GLP-1 on glucagon
secretion is heavily debated. Glucagon inhibition is also said
to be glucose-dependent, although it is unclear what is meant
by this. We hypothesise here that GLP-1 does not inhibit glu-
cagon secretion during hypoglycaemia because the inhibition
depends on somatostatin secretion, which in turn is dependent
on glucose levels.
Methods We used the perfused mouse pancreas model to in-
vestigate this hypothesis.
Results We found that, in this model, GLP-1 was able to
significantly inhibit glucagon secretion from pancreatic alpha
cells at all glucose levels tested: 6.0, 1.5 and 0.5 mmol/l
(−27.0%, −37.1%, and −23.6%, respectively), and the de-
crease in glucagon secretion was invariably accompanied by
an increase in somatostatin secretion (+286.8%, +158.7%, and
+118.8%, respectively). Specific blockade of somatostatin re-
ceptor 2 increased glucagon secretion (+118.8% at 1.5 mmol/l
glucose and +162.9% at 6.0 mmol/l glucose) and completely
eliminated the inhibitory effect of GLP-1.
Conclusions/interpretation We have shown here that the
glucagon-lowering effect of GLP-1 is entirely mediated
through the paracrine actions of somatostatin in the perfused
mouse pancreas. However, in this model, the inhibitory effect
of GLP-1 was preserved at hypoglycaemic levels, leaving
unanswered the question of how this is avoided in vivo in
individuals treated with GLP-1 receptor agonists.
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GLP-1 Glucagon-like peptide-1
GLP-1R Glucagon-like peptide-1 receptor
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Introduction
Type 2 diabetes is a rapidly increasing health issue worldwide.
Over the last decade, glucagon-like peptide-1 (GLP-1) ana-
logues and inhibitors of the GLP-1-degrading enzyme
dipeptidyl peptidase-4 (DPP-4) have been implemented as
treatments for type 2 diabetes [1, 2]. These drugs stimulate
insulin secretion but have the advantage that they carry a low
risk of causing hypoglycaemia [1, 3], which is a common side
effect of insulin treatment.
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Themechanism of action of GLP-1 analogues is to increase
the glucose sensitivity of beta cells, thereby enhancing
glucose-induced insulin secretion, but they also inhibit gluca-
gon secretion from the alpha cells [4]. This inhibition of glu-
cagon secretion may account for about half of the blood
glucose-lowering activity of GLP-1 [5]. Although the effect
of GLP-1 on insulin secretion in accordance with the mecha-
nism of action is clearly dependent on ambient glucose con-
centrations, with considerable amplification at increasing glu-
cose concentrations [6], the glucagon inhibition is also said to
be glucose-dependent, although it is unclear what is meant by
this. In healthy individuals, glucagon secretion is clearly
inhibited by GLP-1 at glucose concentrations around normal
fasting levels (4.5–5.5 mmol/l), whereas at higher glucose
concentrations, the glucose-induced inhibition predominates
and little additional inhibition by GLP-1 is detectable. At low-
er glucose levels, the inhibitory effect wanes, and at
hypoglycaemic levels, which themselves stimulate glucagon
secretion, the inhibition by GLP-1 is completely lost [7]. The
glucose dependency of both the insulin stimulation and the
glucagon inhibition is important clinically, as it means that
hypoglycaemia does not normally occur during therapy with
GLP-1 analogues.
The mechanism of the inhibitory effect of GLP-1 on glu-
cagon secretion is highly controversial. One possibility is a
paracrine inhibition by insulin (the intra-islet hypothesis) [8].
Although this would be compatible with the lack of an inhib-
itory effect during hypoglycaemia (when insulin secretion is
halted), this cannot be the only mechanism, as GLP-1 strongly
inhibits glucagon secretion in individuals with long-standing
type 1 diabetes [9, 10].
Another possibility is a direct action of GLP-1 on the alpha
cells [11]. This has been heavily debated because it is unclear
how many alpha cells actually express the GLP-1 receptor
(GLP-1R), and if they do, how many GLP-1Rs are actually
expressed. Everything from 0% to 100% of pancreatic alpha
cells has been reported to express the GLP-1R [12, 13]. One
recent study from Rorsman’s group suggested that alpha cells
do express GLP-1Rs, but in very low numbers [14]. A major
reason for the controversy regarding GLP-1-R localisation has
been the lack of specific GLP-1R antibodies [15–17].
Apparently, however, monoclonal antibodies raised against
the isolated ectodomain of the GLP-1R show superior specific-
ity. A recent study employing such an antibody raised against
the human GLP-1R did not identify any GLP-1Rs on alpha
cells in human islets [18], but there might be species differ-
ences.We are currently working with a similar antibody against
the murine GLP-1R in our own lab in order to further evaluate
the localisation of the GLP-1R in the endocrine pancreas.
A third possibility is a paracrine inhibitory action by so-
matostatin from neighbouring delta cells, as GLP-1 powerful-
ly stimulates somatostatin secretion [19, 20]. Blockade of such
an interaction using a somatostatin receptor 2 (SSTR2)
antagonist eliminated the inhibitory activity of GLP-1 in per-
fused rat pancreas [19]. The hypothesis for the current study
was that GLP-1 does not inhibit glucagon secretion during
hypoglycaemia because the inhibition depends on somatostat-
in secretion, which in turn—like insulin secretion—is
glucose-dependent and almost non-existent at very low glu-
cose concentrations.
Methods
Test substances GLP-1 (7-36-amide), somatostatin-14 and
SSTR2 antagonist were ordered from Bachem, Heidelberg,
Germany (catalogue nos H-6795, H-1490 and H-6056, respec-
tively). All three were diluted in phosphate buffer containing
1% (wt/vol.) human serum albumin, and stock solutions were
stored at −20°C until the experiments were carried out. On the
days when the experiments were run, the stocks were diluted in
perfusion buffer (see below) and kept at 4°C until infusion. The
final perfusate concentrations were 1 nmol/l for GLP-1 and
somatostatin, and 100 nmol/l for the SSTR2 antagonist. The
positive control, L-arginine, was purchased from Sigma-
Aldrich, Munich, Germany (catalogue no. A6969) and dis-
solved in perfusion buffer immediately prior to infusion (final
concentration 10mmol/l). The final concentrations of GLP-1 in
the perfusate were about 10 times higher than the normal phys-
iological peak concentration [21], but similar to those observed
after gastric bypass [22], and were chosen in order to minimise
variation and compensate for the loss of endogenous factors
usually securing full responsiveness in vivo.
Animals Female C57BL/6 mice (9–12 weeks, 19–23 g), bred
in our own animal facility and with free access to standard
rodent chow and water, were used for the experiments. They
were housed 2–8 mice per cage under a 12 h light/dark cycle.
All animal studies were carried out in accordance with local
and international guidelines and with permission from the
Danish Veterinary and Food Administration.
Isolated perfused mouse pancreas Non-fasted mice were
anaesthetised by i.p. injection of ketamine/xylazine (0.1 ml/
20 g; ketamine 90 mg/kg [Ketaminol Vet.; MSD Animal
Health, Madison, NJ, USA]; xylazine 10 mg/kg [Rompun Vet.;
Bayer Animal Health, Leverkusen, Germany]) and the entire
abdominal cavity was exposed. The pancreas was then isolated
in situ from the circulation as previously described [23].
In brief, the pancreas and duodenum were dissected free of
the surrounding tissues, and the abdominal aorta and portal
vein were cannulated for single-pass perfusion of the pancreas
with a modified Krebs–Ringer bicarbonate buffer containing
0.1% (wt/vol.) BSA, 5% (wt/vol.) dextran T-70 (to provide
adequate oncotic pressure; Dextran Products, Scarborough,
ON, Canada), 0.5, 1.5 or 6.0 mmol/l glucose, 5 mmol/l each
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of pyruvate, fumarate and glutamate, and 5 ml/l Vamin (a
mixture of essential and non-essential amino acids;
Fresenius Kabi, Copenhagen, Denmark) (the last four sub-
strates were omitted in the buffer with 0.5 mmol/l glucose);
pH was adjusted to 7.4 with 5 mmol/l HCl. The buffer was
oxygenated with a 95% O2/5% CO2 (vol/vol.) mixture and
pre-heated to approximately 39°C.
After establishing the perfusion flow through the pancreas,
the mouse was euthanised by perforating the diaphragm. Test
substances were infused via a side-arm syringe. The flow rate
was kept constant at 2.0 ml/min, and 1 min effluent samples
were collected from the venous cannula using a fraction col-
lector (Frac-920; GE Healthcare, Brøndby, Denmark) and
stored at −20°C until analysis.
Hormone analyses Effluent samples (1 min), collected from
the venous cannula, were analysed for glucagon, somatostatin
and insulin by in-house RIA. Glucagon concentrations were
measured using C-terminally directed assay, employing anti-
serum 4305, which only detects glucagon of pancreatic origin
[24], a technique that has recently been validated against MS
[25]. Somatostatin was measured using a rabbit antiserum
raised against synthetic cyclic somatostatin (1758),
recognising both somatostatin-14 and somatostatin-28 [26,
27]. Insulin concentrations were determined using guinea
pig antiserum raised against porcine insulin (2006-3), which
cross-reacts strongly with human, rat and mouse insulin [28].
All assays perform well in perfusate with high precision
(CV < 5%), sensitivity (<1 pmol/l) and accuracy (recovery
of added hormones within ±10% of expected values and linear
dilutions).
Hormone concentrations were measured in all 1 min efflu-
ent portions, allowing detailed and reliable determination of
secretory dynamics. Data were plotted and analysed using
GraphPad Prism software, version 6.0 (La Jolla, CA, USA).
For statistical analysis of the data, accumulated hormone out-
puts over 10 min periods of test agent infusions were com-
pared with the preceding 10 min ‘resting periods’. For the L-
arginine controls, the maximal peak value was compared with
the preceding 10 min ‘resting period’.
Results
Responses to GLP-1 at 0.5, 1.5 and 6.0 mmol/l glucose
Initial mouse pancreas perfusion experiments were performed
with GLP-1 and L-arginine infusions at 1.5 and 6.0 mmol/l
glucose (Fig. 1a–c). The L-arginine was included as a positive
control and resulted in large increases in glucagon secretion at
both low (1.5 mmol/l) and normal (6.0 mmol/l) glucose levels
(+693.9% and +590.3%, respectively) (Fig. 1a,). In parallel to
this, L-arginine also elicited strong peaks in somatostatin se-
cretion (+319.4% and 300.0% at 1.5 and 6.0 mmol/l,
respectively, i.e. identical fractional increases, but much
higher absolute outputs at high glucose; Fig. 1b). At low glu-
cose concentrations (1.5 mmol/l), L-arginine had no effect on
insulin secretion, whereas a strong peak in insulin secretion
(+274.4%) was seen at 6.0 mmol/l glucose (Fig. 1c). These
responses to L-arginine were as expected from previous stud-
ies [23, 29].
In our perfusion model, an inhibitory effect of GLP-1 on
glucagon secretion (−37.1%) was seen at 1.5 mmol/l
glucose—coinciding with an increase in somatostatin secretion
(+158.7%) (Fig. 1a, b). There was no change in insulin at this
low glucose concentration (Fig. 1c). At 6.0 mmol/l glucose,
GLP-1 also decreased glucagon secretion (−27.0%) and con-
comitantly increased somatostatin secretion (+286.8%)
(Fig. 1a, b). GLP-1 also increased insulin secretion (+28.6%)
at 6.0 mmol/l glucose (Fig. 1c). The change in glucose
concentration from 1.5 to 6.0 mmol/l did not have a major
influence on basal somatostatin secretion, which was very low
in these experiments, presumably because of the glucose depri-
vation in the first part of the experiment. However, the absolute
responses to both L-arginine and GLP-1 were clearly potentiat-
ed at the higher glucose concentrations (see also Fig. 2).
The marked glucagon response to GLP-1 even at
1.5 mmol/l glucose was unexpected, and we therefore studied
the effect using an almost substrate-free set-up (buffer without
pyruvate, fumarate, glutamate and Vamin) with only
0.5 mmol/l glucose (Fig. 1d, e). The fractional L-arginine re-
sponses in this set-up (+673.3 and +350% increases in gluca-
gon and somatostatin secretion, respectively) were compara-
ble to what we observed at 1.5 mmol/l glucose (Fig. 1a, b). In
this substrate-deprived buffer, the effect of GLP-1 was pre-
served, with a significant decrease in glucagon secretion
(−23.6%), but paralleled by an increase in somatostatin secre-
tion (+118.8%) (Fig. 1d, e). No insulin was detected.
It should be noted, however, that the pancreas preparations
were probably stressed during these substrate-deprived exper-
iments. This was evident from high perfusion pressures and
oedema of the pancreatic tissue (data not shown). Out of six
attempted experiments, only two were completed to 110 min,
two were discontinued 70 min into the protocol, and two were
aborted and discarded after 30–40 min. Therefore, the first
70 min of data in Fig. 1d, e represents n = 4, whereas the
end of the protocol (71–110 min), including the positive con-
trol, represents only n = 2.
Responses to GLP-1 in the absence and presence of a
SSTR2 antagonist In the next set of experiments, GLP-1 stim-
ulation was carried out at both low and normal glucose levels in
the absence or presence of an SSTR2 antagonist (Fig. 2). The
positive control, L-arginine, yielded the expected responses,
showing peaks in the secretion of glucagon and somatostatin at
both 1.5 and 6.0 mmol/l glucose (+68.2% and +119.7% for glu-
cagon and +206.5% and+365.9% for somatostatin, respectively),
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but only at 6.0 mmol/l glucose for insulin (+2066.7%) (Fig. 2a–
f). At the low glucose levels (1.5 mmol/l), GLP-1 lowered glu-
cagon secretion (−11.5%), and this coincided with an increase in
somatostatin secretion (+92.7%).
At 1.5 mmol/l glucose, the addition of the SSTR2 antagonist
strongly increased baseline glucagon secretion (+118.8%), and
the suppressive effect of GLP-1 on glucagon secretion was
eliminated in the presence of the SSTR2 antagonist (Fig. 2a).
This was observed even though the somatostatin response to
GLP-1 was much higher (+167.5%) during the SSTR2 antag-
onist infusion period at 1.5 mmol/l glucose (Fig. 2b). At this
glucose concentration, basal somatostatin secretion approxi-
mately doubled (+101.9%) when the SSTR2 antagonist was
applied. Clearly, addition of the SSTR2 antagonist increased
the somatostatin responses to bothGLP-1 and glucose, presum-
ably by interrupting a negative feedback effect. There was no
insulin secretion at 1.5 mmol/l glucose (Fig. 2c).
At normal glucose levels (6 mmol/l; Fig. 2d–f), GLP-1
clearly increased somatostatin secretion (+111.8%) and
concomitantly decreased glucagon secretion (−21.7%).
When the SSTR2 antagonist was infused, baseline glucagon
secretion was dramatically increased (+162.9%), and the in-
hibitory effect of GLP-1 on glucagon secretion was lost de-
spite a preserved somatostatin response to GLP-1 (+114.2%)
(Fig. 2 d, e). As observed with the glucagon response to
SSTR2 antagonist infusion, baseline somatostatin secretion
also showed a more pronounced increase at 6.0 mmol/l
(+121.5%; Fig. 2e) than at 1.5 mmol/l glucose (+101.9%;
Fig. 2b) on addition of the SSTR2 antagonist.
GLP-1 infusion triggered a moderate increase in insulin
secretion regardless of the presence of the SSTR2 antagonist
(+101.7% and +62.3% without or with the SSTR2 antagonist,
respectively; Fig. 2f). Addition of the SSTR2 antagonist did
not significantly change baseline insulin secretion at
6.0 mmol/l glucose, but did elicit a peak immediately after
the infusion was started, much like the typical first-phase re-
sponse observed for insulin when glucose concentration is
increased (Fig. 2f).
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Fig. 1 Concentrations of
glucagon, somatostatin and insulin
in venous effluents from mouse
pancreas perfusion experiments
with infusion of GLP-1,
somatostatin and
L-arginine at various glucose
concentrations. Green bars,
infusion period of 1 nmol/l
GLP-1; blue bars, infusion period
of 1 nmol/l somatostatin; grey bars,
infusion period of 10 mmol/l
L-arginine. (a–c) GLP-1 and
L-arginine stimulation at 1.5 and
6.0 mmol/l glucose, n = 5. The
dotted line at 75 min indicates the
mid-experiment transition from
1.5mmol/l to 6.0mmol/l glucose in
the perfusion medium. (a)
Glucagon output; (b) somatostatin
output; (c) insulin output. (d–e)
GLP-1, somatostatin and L-arginine
stimulation at 0.5 mmol/l glucose
(buffer without pyruvate, fumarate,
glutamate and Vamin). The first
70 min of data in (d–e) represents
n = 4, whereas the end of the
protocol (71–110 min), including
the positive control, represents only
n = 2. (d) Glucagon output; (e)
somatostatin output. No insulin was
detected at 0.5 mmol/l glucose.
L-arginine was used as a positive
control. Results are presented as
mean + SEM
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Discussion
Using the perfused mouse pancreas model, we set out to ex-
plore why GLP-1-based therapy carries a very low risk of
hypoglycaemic events in spite of its ability to inhibit glucagon
secretion [1, 3]. We hypothesised that it might be due to a lack
of GLP-1-induced somatostatin secretion at low blood glucose
levels. GLP-1 stimulation was carried out on perfused mouse
pancreas preparations at both low and normal glucose levels,
as well as with and without an SSTR2 antagonist. We show
here that the basal somatostatin secretion and response to
GLP-1 were strongly dependent on perfusate glucose concen-
trations. Furthermore, the somatostatin response and the inhi-
bition of glucagon secretion were inversely correlated.
In the first series of experiments, we investigated the impact
of GLP-1-infusions on the pancreatic secretion of glucagon,
somatostatin and insulin. We found that GLP-1 did not affect
insulin secretion at low glucose levels (1.5 and 0.5 mmol/l;
Fig. 1c, Fig. 2c), whereas GLP-1 increased insulin secretion
at normal glucose levels (6.0 mmol/l; Fig. 1c, Fig. 2f). This
was consistent with our expectations based on literature de-
scribing how the insulinotropic action of GLP-1 depends on
simultaneous exposure of the beta cells to glucose [30–33].
However, contrary to what we anticipated, we observed that
the inhibitory action of GLP-1 on glucagon secretion was
retained at low glucose levels (1.5 and 0.5 mmol/l) (Fig. 1a, d,
Fig. 2a). This clearly illustrates the differential actions of
GLP-1 on hormone secretion from the alpha and beta cells.
The action ofGLP-1 on beta cells is well described and relies
on the expression of GLP-1Rs that can be activated and thereby
potentiate glucose-induced insulin secretion once plasma glu-
cose reaches a certain threshold level [30, 33]. However, there
is much uncertainty regarding the expression of the GLP-1R on
alpha cells. Some groups have identified GLP-1Rs on all alpha
cells, some have found them on only a subset of alpha cells, and
some have been unable to identify them on alpha cells [11, 12,
34–36]. It is therefore highly plausible that the primary route of
communication for GLP-1 to the alpha cells is not via direct
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Fig. 2 Concentrations of
glucagon, somatostatin and
insulin in venous effluents from
mouse pancreas perfusion
experiments with infusion of
GLP-1 and SSTR2 antagonist.
Green bars, infusion period of
1 nmol/l GLP-1; grey bars,
infusion period of 10 mmol/l L-
arginine. The dotted line at 40min
indicates the start of the SSTR2
antagonist infusion period, which
was continued until completion of
the protocol. (a–c) GLP-1
stimulation without and with the
presence of an SSTR2 antagonist
at 1.5 mmol/l glucose, n = 5. (a)
Glucagon output; (b)
somatostatin output; (c) insulin
output. (d–f) GLP-1 stimulation
without and with the presence of
an SSTR2 antagonist at 6 mmol/l
glucose, n = 6. (d) Glucagon
output; (e) somatostatin output;
(f) insulin output. L-arginine was
used as a positive control. Results
are presented as mean + SEM
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interaction with these cells, but instead via an indirect route. An
indirect mechanism could very well involve somatostatin re-
leased from neighbouring delta cells, for which the evidence
regarding expression of the GLP-1R is stronger [30, 35, 37].
The results presented in the present study strongly support
this hypothesis. According to our original hypothesis, GLP-1
should not be able to inhibit glucagon secretion during
hypoglycaemia because no somatostatin would be present un-
der these conditions. In our perfused mouse pancreas model,
however, it was not possible to eliminate somatostatin secre-
tion completely by conducting the experiments under even
severely hypoglycaemic conditions (Fig. 1b, e, Fig. 2b).
But why is this mechanism lost in humans during
hypoglycaemia? One possibility might be that somatostatin tone
in the pancreas is usually neurally regulated, as well as being
influenced by glucose concentrations [38]. It has previously been
shown that somatostatin secretion from the pancreatic delta cells
may be under a tonic vagal control in vivo [39]. In our model, all
extrinsic neural communication to the richly innervated islets
[40] was eliminated owing to the nature of the surgical prepara-
tion (see Methods). This may relieve a possible tonic vagal inhi-
bition that could be the cause of the sustained somatostatin se-
cretion seen in our experiments even at extremely low glucose
levels. Indeed, efferent vagal activity is greatly stimulated by
hypoglycaemia [41, 42]. Nevertheless, our results show that,
regardless of glucose concentration, GLP-1-induced inhibition
of glucagon secretion is always paralleled by a peak in somato-
statin secretion.
In the second series of experiments, we eliminated somato-
statin signalling to the alpha cells by applying a specific SSTR2
antagonist. It has previously been shown that SSTR2 is the
main somatostatin receptor subtype expressed on rodent alpha
cells [43], and it has been suggested that this receptor is respon-
sible for intraislet regulation of glucagon secretion by somato-
statin [44–46]. Our results clearly confirm and extend this no-
tion as we observed a dramatic increase in baseline glucagon
secretion on addition of the SSTR2 antagonist at both 1.5 and
6.0 mmol/l glucose (Fig. 2a, d); interestingly, glucagon levels
were nearly identical, regardless of the glucose concentration,
suggesting that the SSTR2 is somehow also involved in the
glucose-mediated inhibition of glucagon secretion.
The possibility that somatostatin could be involved in the
inhibition of glucagon secretion by glucose is supported by
several reports indicating that isolated alpha cells may actually
respond to glucose with an increased secretion [36, 47]. The
possible role of somatostatin in glucose-mediated inhibition of
glucagon secretion will be the subject of further studies.
Furthermore, the SSTR2 antagonist also increased baseline
somatostatin secretion at both glucose levels (Fig. 2b, e), dem-
onstrating that SSTR2 must be involved in a somatostatin-
related autocrine feedback inhibition of the delta cells.
The SSTR2 antagonist did not cause any significant change
in baseline insulin secretion (Fig. 2c, f). This is consistent with
the fact that somatostatin receptor 5 (SSTR5), rather than
SSTR2, may be the main somatostatin receptor on beta cells
[45, 48]. The SSTR2 antagonist did, however, elicit a short
peak in insulin secretion immediately after addition, which
could be caused by a local action of the dramatically increased
glucagon secretion at this point [49]. The insulin response to
GLP-1 at 6.0 mmol/l glucose was considerably larger before
than after addition of the SSTR2 antagonist (+101.7% before
vs +62.3% after). Although this difference was not statistically
significant, it could probably be ascribed to the greater level of
somatostatin present during the second GLP-1 infusion, sup-
pressing insulin secretion through SSTR5 [45, 48].
Most importantly, we show here that GLP-1-induced suppres-
sion of glucagon secretion in the mouse pancreas is eliminated in
the presence of an SSTR2 antagonist. These results are in line
with previous studies on perfused rat pancreas in our own labo-
ratory [19] as well as that of Coy’s group [44]. Other studies
identifying somatostatin as a very important paracrine regulator
of pancreatic glucagon secretion have been conducted in human
islets [50], islets from SSTR2 knockout mice [45] and somato-
statin knockout mice both in isolated islets and in vivo [51].
However, Rorsman’s group recently estimated that approximate-
ly 1% of the alpha cell population in mouse islets express the
GLP-1R, and demonstrated that this small population of GLP-
1R-positive cells was sufficient to induce suppression of gluca-
gon secretion in response to GLP-1 over a wide range of glucose
concentrations (1–20 mmol/l), based on a theory that limited
cAMP responses inhibit glucagon secretion (whereas large re-
sponses stimulate secretion). They found no effect of GLP-1 on
somatostatin secretion, and addition of a specific SSTR2 antago-
nist did not influence the inhibitory effect of GLP-1 on glucagon
secretion [14].
However, isolated cells are not optimal for studies of
intraislet paracrine relationships. In the isolated perfusedmouse
pancreas, the cytoarchitecture and microvasculature are pre-
served, thereby ensuring that also paracrine interactions be-
tween the islet cells are preserved. In isolated islets, multidirec-
tional diffusion of both extrinsic and intrinsic hormones inevi-
tably occurs during whole-islet incubations, as opposed to per-
fusion via the natural microcirculation system of the islets.
Insulin has been suggested to play a major role as a para-
crine regulator of glucagon secretion (the intraislet hypothesis),
but in our experiments at hypoglycaemic glucose levels, insu-
lin (and other beta cell-derived factors, e.g. amylin) is not a
significant factor. In rodents, alpha and delta cells are found in
close proximity in the periphery of the islets [8, 52, 53], further
supporting the existence of paracrine interactions between the
alpha and delta cells. Furthermore, the close relationship be-
tween alpha and delta cells is also a key point in terms of the
potential for translating our results to humans. Thus, regardless
of differences in the overall structure and morphology of the
islets between rodents and humans, the close relationship be-
tween alpha and delta cells appears to be universal [54, 55].
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Regarding the possibility that insulin could be involved in
suppressing glucagon secretion, we did not, as mentioned,
find any evidence of this in our experiments. We found that
GLP-1 was able to decrease glucagon secretion and concom-
itantly increase somatostatin secretion even at very low glu-
cose levels, whereas insulin secretion was unaffected by GLP-
1 infusion under these conditions. The sensitivity of the per-
fusion system with respect to detecting changes in insulin
secretion is extreme: the release of even a few femtomoles
of insulin would have been detected.
According to the intra-islet hypothesis, insulin acts as a
paracrine inhibitor of glucagon secretion [8], but that hypoth-
esis is poorly compatible with the results presented here. First,
glucagon is inhibited by GLP-1 even in conditions where
insulin is absent (1.5 and 0.5 mmol/l glucose) (Fig. 1a, d,
Fig. 2a) , and, second, the glucagon response to
GLP-1-stimulation is eliminated in the presence of an
SSTR2 antagonist despite a preserved GLP-1-induced peak
in insulin under these conditions (Fig. 2f). In addition to the
present results, the intraislet hypothesis has previously been
investigated in our laboratory using the perfused mouse and
rat pancreas models and has been found to be inconsistent
with the experimental data (unpublished results, B.
Svendsen, J. Pedersen, J. de Heer, and J. J. Holst).
Furthermore, with regard to the effects of GLP-1, the intraislet
hypothesis is also inconsistent with the fact that GLP-1 retains
the ability to inhibit glucagon secretion in individuals with
type 1 diabetes with no residual beta cell population [9, 10].
A direct effect of GLP-1 on GLP-1Rs expressed on the alpha
cells also seems unlikely because a direct GLP-1-induced in-
hibition of glucagon secretion would not have been eliminated
in the presence of an SSTR2 antagonist.
Part of the intra-islet hypothesis rests on a directional flow
within the islets from the beta cell core to the mantle, with
alpha and delta cells. However, there seems to be agreement in
the literature that the alpha and delta cells are generally ap-
posed. Therefore, the paracrine relationship between these
cells should not be affected by the intraislet flow, regardless
of its direction.
ConclusionsOur study shows that GLP-1 increases the secre-
tion of somatostatin and concomitantly decreases the secretion
of glucagon at all glucose levels. Furthermore, the decreased
glucagon secretion in response to GLP-1 infusion is complete-
ly eliminated in the presence of an SSTR2 antagonist. Thus,
we show here that the glucagon-lowering effect of GLP-1 in
mouse pancreas is entirely mediated through the paracrine
actions of somatostatin.
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